AnaptysBio Inc (ANAB)
33.98
-1.04
(-2.98%)
USD |
NASDAQ |
Oct 04, 16:00
34.01
+0.02
(+0.07%)
After-Hours: 20:00
AnaptysBio Shareholders Equity (Annual): 88.10M for Dec. 31, 2023
Shareholders Equity (Annual) Chart
Historical Shareholders Equity (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 88.10M |
| December 31, 2022 | 262.10M |
| December 31, 2021 | 356.43M |
| December 31, 2020 | 396.73M |
| December 31, 2019 | 405.01M |
| December 31, 2018 | 486.36M |
| Date | Value |
|---|---|
| December 31, 2017 | 307.58M |
| December 31, 2016 | 39.27M |
| December 31, 2015 | 42.34M |
| December 31, 2014 | 5.993M |
| December 31, 2013 | 0.145M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Annual) Range, Past 5 Years
88.10M
Minimum
2023
405.01M
Maximum
2019
301.67M
Average
356.43M
Median
2021
Shareholders Equity (Annual) Benchmarks
| Regeneron Pharmaceuticals Inc | 25.97B |
| Ligand Pharmaceuticals Inc | 700.91M |
| Agios Pharmaceuticals Inc | 811.02M |
| ADMA Biologics Inc | 135.21M |
| Black Diamond Therapeutics Inc | 116.74M |